Down syndrome (DS) is characterized by structural and functional anomalies that are present prenatally and that lead to intellectual disabilities. Later in life, the cognitive abilities of DS individuals progressively deteriorate due to the development of Alzheimer's disease (AD)-associated neuropathology (i.e., β-amyloid (Aβ) plaques, neurofibrillary tangles (NFTs), neurodegeneration, synaptic pathology, neuroinflammation and increased oxidative stress). Increasing evidence has shown that among these pathological processes, neuroinflammation plays a predominant role in AD etiopathology. In AD mouse models, increased neuroinflammation appears earlier than Aβ plaques and NFTs, and in DS and AD models, neuroinflammation exacerbates the levels of soluble and insoluble Aβ species, favoring neurodegeneration. The Ts65Dn (TS) mouse, the most commonly used murine model of DS, recapitulates many alterations present in both DS and AD individuals, including enhanced neuroinflammation. In this study, we observed an altered neuroinflammatory milieu in the hippocampus of the TS mouse model. Pro-inflammatory mediators that were elevated in the hippocampus of this model included proinflammatory cytokine IL17A, which has a fundamental role in mediating brain damage in neuroinflammatory processes. Here, we analyzed the ability of an anti-IL17A antibody to reduce the neuropathological alterations that are present in TS mice during early neurodevelopmental stages (i.e., hippocampal neurogenesis and hypocellularity) or that are aggravated in later-life stages (i.e., cognitive abilities, cholinergic neuronal loss and increased cellular senescence, APP expression, Aβ peptide expression and neuroinflammation). Administration of anti-IL17 for 5 months, starting at the age of 7 months, partially improved the cognitive abilities of the TS mice, reduced the expression of several pro-inflammatory cytokines and the density of activated microglia and normalized the APP and Aβ 1-42 levels in the hippocampi of the TS mice. These results suggest that IL17-mediated neuroinflammation is involved in several AD phenotypes in TS mice and provide a new therapeutic target to reduce these pathological characteristics.
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Introduction
Down syndrome (DS), the most common genetic cause of intellectual disability (Shin et al., 2009) , is caused by a partial or complete triplication of human chromosome 21 (Hsa21). This intellectual disability is primarily caused by prenatal changes in central nervous system growth and differentiation (Lott, 2012; Haydar and Reeves, 2012) . However, later in life, the cognitive abilities of DS individuals progressively decline due to accelerated aging and the development of Alzheimer's disease (AD)-associated neuropathology. The primary hallmarks of AD, such as the accumulation of amyloid plaques comprising β-amyloid (Aβ) peptides, neurofibrillary tangles (NFTs) formed by insoluble deposits of abnormally hyperphosphorylated tau, neuroinflammation, synapse and neuronal loss, and regional atrophy, are present in 100% of individuals with DS by the fourth decade of life (Wilcock and Griffin, 2013; Lott, 2012; Cenini et al., 2012; Sabbagh et al., 2011; Lott and Dierssen, 2010; Teipel and Hampel, 2006) . This high prevalence of AD neuropathology in DS is partially related
